Establishing Shock Index, Pediatric Age-Adjusted (SIPA) Cut Points in Trauma Patients Under 1 Year of Age.

Abstract

Shock Index (SI) is used to predict injury severity and adverse outcomes in trauma patients, but age-adjusted shock index (SIPA) has superior performance in pediatric patients over the age of 1 year. SIPA scores under the age of 1 have not been well studied. This project aimed to establish and evaluate SIPA cut point data points for patients under 1 year of age. Using age-based vital signs, we developed cut point values for patients under 1 year old using our institutional trauma data. All trauma patients under the age of 12 months were included, and clinical outcomes were recorded. SIPA cut points were defined using age specific vital sign limits (SIPA-VS) and tested against optimal cut points defined by ROC analysis (SIPA-ROC) and a cut point of 1.2 (SIPA-Nordin), which is used for patients ages 1-4 years. Student's t-test, chi-square tests, ANOVA, and test characteristics were used to analyze groups. A total of 609 pediatric trauma patients under the age of 12 months were identified from 2018 to 2022. SIPA scores were calculated for 483 patients. There were 406 patients with blunt trauma and 17 with penetrating. SIPA-Nordin was elevated in 81.6% (n = 397) of patients, compared to SIPA-VS 21% (n = 101) and SIPA-ROC 31% (n = 150). In comparison to SIPA-Nordin, both SIPA-VS and SIPA-ROC score exhibited superior specificity and negative predictive values (NPV) for multiple outcomes. Elevated SIPA-ROC scores had statistically significant associations with ICU admission, mechanical ventilation, severe anemia, transfusion during hospital admission, and in-hospital mortality. SIPA is a useful tool in identifying patients at risk for several complications of severe traumatic injury. SIPA cut points had high NPV and specificity for many outcomes. This study proposes cut point values that may aid in clinical decision-making for trauma patients under 1 year of age.Level of Evidence: Level IV Retrospective Review.